Last reviewed · How we verify
Erenumab Prefilled Syringe
At a glance
| Generic name | Erenumab Prefilled Syringe |
|---|---|
| Sponsor | David Jang, M.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action (PHASE4)
- Fremanezumab, Migraine and Sleep (PHASE4)
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (PHASE2)
- Galcanezumab for Vestibular Migraine (PHASE2)
- Erenumab for Idiosyncratic Facial Pain (PHASE4)
- Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) (PHASE2)
- Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (PHASE2)
- Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erenumab Prefilled Syringe CI brief — competitive landscape report
- Erenumab Prefilled Syringe updates RSS · CI watch RSS
- David Jang, M.D. portfolio CI